The Medicines Co. nets $400M nod for UTI antibacterial treatment

30th August 2017 Uncategorised 0

Doctors treating patients with complicated urinary tract infections will soon have a new tool in their arsenal with the FDA’s Tuesday approval for Vabomere, a combination of the antibacterial meropenem and vaborbactam, a component to combat bacterial resistance.

More: The Medicines Co. nets 0M nod for UTI antibacterial treatment
Source: fierce